4DMEDICAL Ltd (4DX) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.446x

Based on the latest financial reports, 4DMEDICAL Ltd (4DX) has a cash flow conversion efficiency ratio of 0.446x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-12.66 Million ≈ $-8.96 Million USD) by net assets (AU$-28.40 Million ≈ $-20.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

4DMEDICAL Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how 4DMEDICAL Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 4DMEDICAL Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

4DMEDICAL Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of 4DMEDICAL Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
SJM HOLDINGS UNSP.ADR/4
F:3MG1
N/A
Hyundai Mar&Fi
KO:001450
0.095x
Guangdong Yizumi Precision Machinery Co Ltd
SHE:300415
-0.009x
U-Ming Marine Transport Corp
TW:2606
0.063x
West China Cement Limited
F:WFG1
0.039x
Innoviva Inc
NASDAQ:INVA
0.046x
SEAZEN GROUP LTD. HD-001
F:6FLA
N/A
Anupam Rasayan India Limited
NSE:ANURAS
0.012x

Annual Cash Flow Conversion Efficiency for 4DMEDICAL Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of 4DMEDICAL Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market value of 4DMEDICAL Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$64.24 Million
≈ $45.45 Million
AU$-34.48 Million
≈ $-24.39 Million
-0.537x 0.00%
2024-12-31 AU$64.24 Million
≈ $45.45 Million
AU$-34.48 Million
≈ $-24.39 Million
-0.537x -23.33%
2024-06-30 AU$70.93 Million
≈ $50.19 Million
AU$-30.87 Million
≈ $-21.84 Million
-0.435x 0.00%
2023-12-31 AU$70.93 Million
≈ $50.19 Million
AU$-30.87 Million
≈ $-21.84 Million
-0.435x -37.29%
2023-06-30 AU$71.46 Million
≈ $50.56 Million
AU$-22.65 Million
≈ $-16.03 Million
-0.317x 0.00%
2022-12-31 AU$71.46 Million
≈ $50.56 Million
AU$-22.65 Million
≈ $-16.03 Million
-0.317x +25.34%
2022-06-30 AU$59.51 Million
≈ $42.11 Million
AU$-25.27 Million
≈ $-17.88 Million
-0.425x 0.00%
2021-12-31 AU$59.51 Million
≈ $42.11 Million
AU$-25.27 Million
≈ $-17.88 Million
-0.425x -143.76%
2021-06-30 AU$83.36 Million
≈ $58.98 Million
AU$-14.52 Million
≈ $-10.27 Million
-0.174x 0.00%
2020-12-31 AU$83.36 Million
≈ $58.98 Million
AU$-14.52 Million
≈ $-10.27 Million
-0.174x -126.89%
2020-06-30 AU$-11.81 Million
≈ $-8.36 Million
AU$-7.65 Million
≈ $-5.41 Million
0.648x 0.00%
2019-12-31 AU$-11.81 Million
≈ $-8.36 Million
AU$-7.65 Million
≈ $-5.41 Million
0.648x +151.07%
2019-06-30 AU$4.56 Million
≈ $3.22 Million
AU$-5.78 Million
≈ $-4.09 Million
-1.269x 0.00%
2018-12-31 AU$4.56 Million
≈ $3.22 Million
AU$-5.78 Million
≈ $-4.09 Million
-1.269x -41.85%
2018-06-30 AU$3.78 Million
≈ $2.67 Million
AU$-3.38 Million
≈ $-2.39 Million
-0.894x 0.00%
2017-12-31 AU$3.78 Million
≈ $2.67 Million
AU$-3.38 Million
≈ $-2.39 Million
-0.894x -34.64%
2017-06-30 AU$3.25 Million
≈ $2.30 Million
AU$-2.16 Million
≈ $-1.53 Million
-0.664x 0.00%
2016-12-31 AU$3.25 Million
≈ $2.30 Million
AU$-2.16 Million
≈ $-1.53 Million
-0.664x +12.45%
2016-06-30 AU$926.64K
≈ $655.66K
AU$-703.00K
≈ $-497.42K
-0.759x 0.00%
2015-12-31 AU$926.64K
≈ $655.66K
AU$-703.00K
≈ $-497.42K
-0.759x -887.57%
2015-06-30 AU$532.93K
≈ $377.08K
AU$-40.94K
≈ $-28.97K
-0.077x 0.00%
2014-12-31 AU$532.93K
≈ $377.08K
AU$-40.94K
≈ $-28.97K
-0.077x --

About 4DMEDICAL Ltd

AU:4DX Australia Medical Devices
Market Cap
$1.66 Billion
AU$2.35 Billion AUD
Market Cap Rank
#6961 Global
#160 in Australia
Share Price
AU$4.09
Change (1 day)
+1.74%
52-Week Range
AU$0.23 - AU$6.80
All Time High
AU$6.80
About

4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function im… Read more